Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RCUS
SELLArcus Biosciences, Inc. · Healthcare · United States · $3.6B · Avg Vol: $41M/d
COMPANY DESCRIPTION
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies, targeting critical pathways in immuno-oncology. It specializes in developing small molecule and antibody therapeutics, often pursuing combination strategies to enhance treatment efficacy. Operating in the high-growth immuno-oncology space, Arcus frequently collaborates with larger pharmaceutical companies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 112.0M | 117.0M | 258.0M | 247.0M | 30.2% | 236.0M | 85.1M | 93.1M | -38.6% |
| EPS | -3.71 | -4.15 | -3.14 | -3.29 | — | -3.26 | -3.48 | -3.10 | — |
| Shares | 72.9M | 75.5M | 92.2M | 125.3M | +71.9% | 125.8M | — | — | — |
| Debt | 3.0M | 11.0M | 60.0M | 112.0M | 234.2% | 232.0M | — | — | — |
| Equity | 657.0M | 462.0M | 485.0M | 631.0M | -1.3% | — | — | — | — |
| Op CF | 438.0M | -306.0M | -170.0M | -482.0M | — | -488.0M | — | — | — |
| Inv CF | -413.0M | 194.0M | -84.0M | 66.0M | — | — | — | — | — |
| Fin CF | 33.0M | 33.0M | 277.0M | 488.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RCUS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RCUS | Arcus Biosciences, Inc.(you) | $3.6B | 22 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 20 | SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 22 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 27 | SELL |
| CLDX | Celldex Therapeutics, Inc. | $2.8B | 23 | SELL |
| GPCR | Structure Therapeutics Inc. | $3.5B | 15 | STRONG SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 27 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%